Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate
Abstract
1. Introduction
2. Material and Methods
Study Population
3. Statistical Methods
4. Results
Baseline Characteristics
5. Discussion
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- De Marzo, A.M.; Platz, E.A.; Sutcliffe, S.; Xu, J.; Grönberg, H.; Drake, C.G.; Nakai, Y.; Isaacs, W.B.; Nelson, W.G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007, 7, 256–269. [Google Scholar] [CrossRef]
- Nguyen, D.P.; Li, J.; Tewari, A.K. Inflammation and prostate cancer: The role of interleukin 6 (IL-6). BJU Int. 2014, 113, 986–992. [Google Scholar] [CrossRef]
- Sciarra, A.; Gentilucci, A.; Salciccia, S.; Pierella, F.; Del Bianco, F.; Gentile, V.; Silvestri, I.; Cattarino, S. Prognostic value of inflammation in prostate cancer progression and response to therapeutic: A critical review. J. Inflamm. 2016, 13, 35. [Google Scholar] [CrossRef]
- Yli-Hemminki, T.H.; Laurila, M.; Auvinen, A.; Määttänen, L.; Huhtala, H.; Tammela, T.L.J.; Kujala, P.M. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int. 2013, 112, 735–741. [Google Scholar] [CrossRef]
- Karakiewicz, P.I.; Benayoun, S.; Begin, L.R.; Duclos, A.; Valiquette, L.; McCormack, M.; Benard, F.; Saad, F.; Perrotte, P. Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. Int. J. Clin. Pract. 2007, 61, 425–430. [Google Scholar] [CrossRef] [PubMed]
- Templeton, A.J.; McNamara, M.G.; Šeruga, B.; Vera-Badillo, F.E.; Aneja, P.; Ocaña, A.; Leibowitz-Amit, R.; Sonpavde, G.; Knox, J.J.; Tran, B.; et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. J. Natl. Cancer Inst. 2014, 106, dju124. [Google Scholar] [CrossRef] [PubMed]
- Tang, L.; Li, X.; Wang, B.; Luo, G.; Gu, L.; Chen, L.; Liu, K.; Gao, Y.; Zhang, X. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS ONE 2016, 11, e0153981. [Google Scholar] [CrossRef]
- Templeton, A.J.; Ace, O.; McNamara, M.G.; Al-Mubarak, M.; Vera-Badillo, F.E.; Hermanns, T.; Eruga, B.; Ocaña, A.; Tannock, I.F.; Amir, E. Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Epidemiol. Biomark. Prev. 2014, 23, 1204–1212. [Google Scholar] [CrossRef] [PubMed]
- Keizman, D.; Gottfried, M.; Ish-Shalom, M.; Maimon, N.; Peer, A.; Neumann, A.; Rosenbaum, E.; Kovel, S.; Pili, R.; Sinibaldi, V.; et al. Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram. Oncologist 2012, 17, 1508–1514. [Google Scholar] [CrossRef]
- Guthrie, G.; Charles, K.A.; Roxburgh, C.S.; Horgan, P.G.; McMillan, D.C.; Clarke, S.J. The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer. Crit. Rev. Oncol. 2013, 88, 218–230. [Google Scholar] [CrossRef]
- Langsenlehner, T.; Thurner, E.-M.; Krenn-Pilko, S.; Langsenlehner, U.; Stojakovic, T.; Gerger, A.; Pichler, M. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World J. Urol. 2015, 33, 1661–1667. [Google Scholar] [CrossRef] [PubMed]
- Kwon, Y.S.; Han, C.S.; Yu, J.; Kim, S.; Modi, P.K.; Davis, R.; Park, J.H.; Lee, P.; Ha, Y.-S.; Kim, W.-J.; et al. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk Prostate Cancer. Clin. Genitourin. Cancer 2015, 14, e1–e8. [Google Scholar] [CrossRef] [PubMed]
- Bahig, H.; Taussky, D.; Delouya, G.; Nadiri, A.; Gagonon-Jacques, A.; Bodson-Clermont, P.; Soulieres, D. Neutrophil count is associated with survival in localized prostate cancer. BMC Cancer 2015, 15, 594. [Google Scholar] [CrossRef] [PubMed]
- Turner, N.; Wong, H.-L.; Templeton, A.; Tripathy, S.; Rogers, T.W.; Croxford, M.; Jones, I.; Sinnathamby, M.; Desai, J.; Tie, J.; et al. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int. J. Cancer 2015, 138, 671–678. [Google Scholar] [CrossRef] [PubMed]
- Sano, Y.; Kogashiwa, Y.; Araki, R.; Enoki, Y.; Ikeda, T.; Yoda, T.; Nakahira, M.; Sugasawa, M. Correlation of Inflammatory Markers, Survival, and COX2 Expression in Oral Cancer and Implications for Prognosis. Otolaryngol. Neck Surg. 2018, 158, 667–676. [Google Scholar] [CrossRef] [PubMed]
- Wade, R.G.; Robinson, A.V.; Lo, M.C.I.; Keeble, C.; Marples, M.; Dewar, D.J.; Moncrieff, M.D.S.; Peach, H. Baseline Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Biomarkers of Survival in Cutaneous Melanoma: A Multicenter Cohort Study. Ann. Surg. Oncol. 2018, 25, 3341–3349. [Google Scholar] [CrossRef]
- Robinson, A.V.; Keeble, C.; Lo, M.C.I.; Thornton, O.; Peach, H.; Moncrieff, M.; Dewar, D.J.; Wade, R.G. The neutrophil–lymphocyte ratio and locoregional melanoma: A multicentre cohort study. Cancer Immunol. Immunother. 2020, 69, 559–568. [Google Scholar] [CrossRef]
- Huang, S.; Waldron, J.; Milosevic, M.; Shen, X.; Ringash, J.; Su, J.; Tong, L.; Perez-Ordonez, B.; Weinreb, I.; Bayley, A.J.; et al. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. Cancer 2014, 121, 545–555. [Google Scholar] [CrossRef]
- Kozin, S.V.; Kamoun, W.S.; Huang, Y.; Dawson, M.R.; Jain, R.K.; Duda, D.G. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010, 70, 5679–5685. [Google Scholar] [CrossRef]
- Kane, J.L.; Krueger, S.A.; Hanna, A.; Raffel, T.R.; Wilson, G.; Madlambayan, G.J.; Marples, B. Effect of Irradiation on Tumor Microenvironment and Bone Marrow Cell Migration in a Preclinical Tumor Model. Int. J. Radiat. Oncol. 2016, 96, 170–178. [Google Scholar] [CrossRef]
- Taussky, D.; Bahig, H.; Bahary, J.-P.; Delouya, G.; Souliéres, D.; Azoulay, L.; Yin, H. A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer. Target Oncol. 2017, 12, 695–701. [Google Scholar] [CrossRef] [PubMed]
- Oh, D.S.; Koontz, B.; Freedland, S.J.; Gerber, L.; Patel, P.; Lewis, S.; Yoo, D.S.; Oleson, J.; Salama, J.K. Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. World J. Urol. 2014, 33, 93–97. [Google Scholar] [CrossRef] [PubMed]
- Gutt, R.; Tonlaar, N.; Kunnavakkam, R.; Karrison, T.; Weichselbaum, R.R.; Liauw, S.L. Statin Use and Risk of Prostate Cancer Recurrence in Men Treated with Radiation Therapy. J. Clin. Oncol. 2010, 28, 2653–2659. [Google Scholar] [CrossRef]
- Taussky, D.; Preisser, F.; I Karakiewicz, P.; Tilki, D.; Lambert, C.; Bahary, J.-P.; Delouya, G.; Wistaff, R.; Laskine, M.; Van Nguyen, P.; et al. Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: Results from a large institutional database. Can. J. Urol. 2018, 25, 9509–9515. [Google Scholar]
- Garg, S.K.; Maurer, H.; Reed, K.; Selagamsetty, R. Diabetes and cancer: Two diseases with obesity as a common risk factor. Diabetes Obes. Metab. 2013, 16, 97–110. [Google Scholar] [CrossRef] [PubMed]
- Danzig, M.R.; Kotamarti, S.; A Ghandour, R.; Rothberg, M.B.; Dubow, B.P.; Benson, M.C.; Badani, K.K.; McKiernan, J.M. Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer Prostatic Dis. 2014, 18, 63–68. [Google Scholar] [CrossRef]
Descriptive | Univariate analysis | ||||||
---|---|---|---|---|---|---|---|
n | Frequency (%) | Median | IQR | HR | 95%CI | p | |
CAPRA | |||||||
Low | 355 | 59 | ref | ||||
Intermediate | 248 | 41 | 2.03 | 0.96; 4.22 | 0.054 2 | ||
Age | 66 | 61–70 | 1.02 | 0.97; 1.08 | 0.533 1 | ||
Neutros | 4.2 | 3.3–5.3 | 0.85 | 0.66; 1.08 | 0.233 1 | ||
Lymphos | 1.5 | 1.3–1.9 | 1.03 | 0.85; 1.26 | 0.771 1 | ||
Platelets | 219 | 185–256 | 0.997 | 0.990; 1.003 | 0.292 1 | ||
HB | 147 | 140–154 | |||||
NLR | 2.6 | 2.0–3.7 | 0.72 | 0.54; 0.99 | 0.046 1 | ||
PLR | 140 | 109–181 | 0.99 | 0.99; 1.00 | 0.033 1 | ||
NLR >3 | 241 | 40 | 0.39 | 0.16; 0.97 | 0.035 2 | ||
PLR > 150 | 252 | 42 | 0.46 | 0.21; 1.05 | 0.058 2 | ||
Diabetes | 120 | 20 | 0.46 | 0.14; 1.53 | 0.193 2 | ||
Hypertension | 276 | 46 | 0.84 | 0.40; 1.76 | 0.649 2 | ||
Statin use | 289 | 48 | 0.46 | 0.20; 1.04 | 0.055 2 |
Factor | HR | 95% CI | p |
---|---|---|---|
CAPRA low (ref.) vs. intermediate risk | 2.15 | 1.03; 4.47 | 0.0415 |
NLR > 3 (ref.) vs. ≤ 3 | 0.37 | 0.15; 0.92 | 0.0323 |
Group | n | Number of Recurrences | Percentage Censored | 5-Year Recurrence-Free Survival |
---|---|---|---|---|
Low-risk NLR > 3 | 135 | 2 | 98.5 | 100% |
Low-risk NLR ≤ 3 | 221 | 11 | 95.0 | 97.0% |
Intermediate-risk NLR > 3 | 107 | 4 | 96.3 | 95.0% |
Intermediate-risk NLR ≤ 3 | 141 | 12 | 91.5 | 95.1% |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Taussky, D.; Soulieres, D.; Chagnon, M.; Delouya, G.; Bahig, H. Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate. Cells 2020, 9, 2153. https://doi.org/10.3390/cells9102153
Taussky D, Soulieres D, Chagnon M, Delouya G, Bahig H. Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate. Cells. 2020; 9(10):2153. https://doi.org/10.3390/cells9102153
Chicago/Turabian StyleTaussky, Daniel, Denis Soulieres, Miguel Chagnon, Guila Delouya, and Houda Bahig. 2020. "Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate" Cells 9, no. 10: 2153. https://doi.org/10.3390/cells9102153
APA StyleTaussky, D., Soulieres, D., Chagnon, M., Delouya, G., & Bahig, H. (2020). Systemic Inflammatory Markers Are Predictive of the Response to Brachytherapy in the Prostate. Cells, 9(10), 2153. https://doi.org/10.3390/cells9102153